For instance, a TMB of ≥ 16 mut/Mb showed an ORR of 38% among diverse cancers treated with the anti-PD-L1 atezolizumab, while only 2% of patients responded if the TMB was between 10–15 mutations/mb, perhaps explaining occasional discrepant results for TMB as a biomarker when a cut off of 10 mutations/mb is utilized [30, 14]. The gene discussed is CD274; the disease is cancer.